CrossAssetDataThe Company File
···
CBIO

Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Waltham, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $11 million and a loss of $154 million (its filed statements).

Pre-revenue company Pharmaceutical Preparations Waltham, MA filings since 2003 4 of 9 filed, 5 estimated
Ask the desk about CBIO → Compare CBIO with LFCR → Price chart on TradingView ↗ Full EDGAR file ↗ Watch CBIO →

Sector peers: LFCRIMRXORMPSVRA

5.1/10headline grade
vs its business-model standard
4.7/10past 4.8/10present 5.6/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.1 out of ten, 4 of 9 metrics filed and 5 estimated: past 4.7 out of ten, present 4.8 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 2.1 out of ten. 4 warning events since 2017; the latest 2025-06-18. 21st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 325 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Shareholder treatment (past): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 20 of 100 (family median). 50th percentile among 295 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Financial health (present): 5.6 out of ten. ROE -76%: lost 76¢ per shareholder dollar. Leverage 16%: owes 16¢ per asset dollar. 56th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 3.4 out of ten. bottom 34% of 314 in its family; net margin -1419.6%. 34th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.5 out of ten. CrossAssetData estimate 4.5/10, confidence 35 of 100 (one part). 45th percentile among 414 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Room to expand (future): 6.7 out of ten. top 33% of 272 in its family for room to expand. 67th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 308 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-30 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-30 (on EDGAR). Newest filing: Form 4, 2026-09-18. Filings on record since 2003. Read from EDGAR 2026-10-12.

Who runs it

Brumm, Joshua T (Chief Executive Officer); Lynch, Ryan (Treasurer, Senior Vice President of Finance and Chief Accounting Officer.); Mcneill, Jonathan (President and COO); Scalzo, Richard William (Chief Financial Officer); Im, Ellie Eunkyung (Chief Medical Officer); Pinkas, Jan (Chief Scientific Officer); Doughty, Christopher Grant (Chief Business Officer); Bispham, Barbara Harlin (General Counsel and Corporate Secretary.); Fairmount, Funds Management Llc (director); Fairmount, Healthcare Fund II L.p. (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.